Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer.
Poly(ADP-ribose) polymerase 1 (PARP1) is a key factor responsible for repairing DNA single-strand breaks and maintaining genomic stability. PARP1 inhibitors have achieved remarkable therapeutic efficacy in the treatment of BRCA-mutant breast cancer. However, only a small proportion of breast cancer patients carry BRCA...